aTyr Pharma (ATYR) announced the outcome of a third, pre-planned interim safety analysis conducted by an independent data and safety monitoring board, DSMB, for the ongoing Phase 3 EFZO-FIT study of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis. The DSMB recommended that the study continue without any modifications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR: